DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
ITD 1 (HB3446)
Description:Selective TGF-β signaling inhibitor. Induces cardiomyocyte differentiation in ESCs.
Purity:>98%
-
Ivermectin (IVM) (HB1958)
Description:α7 nicotinic acetylcholine receptor positive allosteric modulator. Activates GluCI/GlyCI chemogenetic channels. Shows antiviral activity.
Purity:>95%
-
IWP 2 (HB0344)
Description:Potent Wnt pathway inhibitor and PORCN inhibitor. Suppresses R1 ESC self-renewal. Used in the production of cardiac organoids.
Purity:>98%
-
IWP 4 (HB3066)
Description:Potent Wnt/β-catenin signaling inhibitor. Induces cardiomyocyte differentiation of hESCs and iPSCs.
Purity:>98%
-
-
JF-NP-26 (Caged-Raseglurant) (HB6127)
Description:Novel, inactive photocaged derivative of raseglurant which can be uncaged with violet light. Shows light-dependent analgesic activity in vivo.
Purity:>98%
-
JHU37152 (DREADD ligand) (HB6252)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%
